Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Zhejiang Hengkang Pranlukast Hydrate

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Pranlukast Hydrate

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 445Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 103177-37-3, Azlaire, Ono-1078, Pranlukast hydrate, Ono 1078, Sb 205312
    Molecular Formula
    C27H23N5O4
    Molecular Weight
    481.5  g/mol
    InChI Key
    NBQKINXMPLXUET-UHFFFAOYSA-N
    FDA UNII
    TB8Z891092
    Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
    2.1.2 InChI
    InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
    2.1.3 InChI Key
    NBQKINXMPLXUET-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5
    2.2 Other Identifiers
    2.2.1 UNII
    TB8Z891092
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 8-(4 (4-phenylbutoxy)benzoyl)amino-2-(tetrazol-5'-yl)-4-oxo-4h-1-benzopyran

    2. Ono 1078

    3. Ono-1078

    4. Ono-rs 411

    5. Ono-rs-411

    6. Sb 205312

    2.3.2 Depositor-Supplied Synonyms

    1. 103177-37-3

    2. Azlaire

    3. Ono-1078

    4. Pranlukast Hydrate

    5. Ono 1078

    6. Sb 205312

    7. Ccn 00401

    8. Rs 411

    9. Pranlukast (inn)

    10. N-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide

    11. Onon

    12. Ono-rs-411

    13. 4-oxo-8-(4-(4-phenylbutoxy)benzoylamino)-2-(tetrazol-5-yl)-4h-1-benzopyran

    14. Chembl21333

    15. N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl)-4-(4-phenylbutoxy)benzamide

    16. Ccn-00401

    17. Rs-411

    18. Tb8z891092

    19. Ncgc00181765-01

    20. Sb-205312

    21. Pranlukast [inn]

    22. N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-p-(4-phenylbutoxy)benzamide

    23. N-(4-oxo-2-(2h-tetrazol-5-yl)-4h-chromen-8-yl)-4-(4-phenylbutoxy)benzamide

    24. 8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4h-1-benzopyran;8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4h-1-benzopyran

    25. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-p-(4-phenylbutoxy)benzamide;n-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-p-(4-phenylbutoxy)benzamide

    26. Azlaire (tn)

    27. Pranlukast [inn:ban]

    28. Sr-05000001474

    29. Unii-tb8z891092

    30. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenylbutoxy)benzamide

    31. N-[4-oxo-2-(2h-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide

    32. Pranlukast [mi]

    33. Pranlukast [mart.]

    34. Schembl3693

    35. Dsstox_cid_23782

    36. Dsstox_rid_80074

    37. Pranlukast [who-dd]

    38. Dsstox_gsid_43782

    39. Mls006010078

    40. Gtpl3634

    41. Ono Rs-411

    42. Dtxsid3043782

    43. Schembl18058592

    44. Chebi:94810

    45. Hms2089h16

    46. Hms3650a14

    47. Hms3714e03

    48. Bcp04577

    49. Hy-b0290

    50. Zinc1542146

    51. Tox21_112952

    52. Ac-696

    53. Bdbm50023198

    54. Mfcd00864631

    55. Akos015967342

    56. Ccg-220661

    57. Db01411

    58. Sb19080

    59. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide

    60. As-15105

    61. Smr004701229

    62. Cas-103177-37-3

    63. Ft-0652673

    64. P2115

    65. C71133

    66. D08408

    67. Ab01275471-01

    68. 177p373

    69. L013134

    70. Q7238392

    71. Sr-05000001474-1

    72. Sr-05000001474-2

    73. Sr-05000001474-3

    74. Brd-k97045029-001-01-9

    75. Brd-k97045029-001-04-3

    76. 8-[4-(4-phenylbutyloxy)benzoyl]amino-2-(tetrazol-5-yl)-4-oxo-4h-1-benzopyran

    77. Benzamide, N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-

    78. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-4(4-phenylbutoxy)benzamide

    79. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide

    80. Benzamide, N-(4-oxo-2-(2h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-

    81. Knt

    82. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide (ono-rs-411)

    83. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide(ono-rs-411)

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 481.5 g/mol
    Molecular Formula C27H23N5O4
    XLogP34.2
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count9
    Exact Mass481.17500423 g/mol
    Monoisotopic Mass481.17500423 g/mol
    Topological Polar Surface Area119 Ų
    Heavy Atom Count36
    Formal Charge0
    Complexity778
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.

    5.2 MeSH Pharmacological Classification

    Leukotriene Antagonists

    A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)

    Anti-Asthmatic Agents

    Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)

    5.3 ATC Code

    R - Respiratory system

    R03 - Drugs for obstructive airway diseases

    R03D - Other systemic drugs for obstructive airway diseases

    R03DC - Leukotriene receptor antagonists

    R03DC02 - Pranlukast

    5.4 Metabolism/Metabolites

    Hepatic

    5.5 Mechanism of Action

    Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.